Rx-360 to have second launch meeting in Europe
NEW YORK The recent launch of an organization that seeks to keep the drug supply chain clean has prompted a similar meeting in Europe.
The Rx-360 Consortium, an organization of drug company executives, suppliers, regulators and healthcare professionals with the goal of keeping the international pharmaceutical supply chain secure, announced that it would have a second launch meeting at the GSK House in Brentford Middlesex, United Kingdom, on Nov. 10. The organization had its original launch meeting in Washington in June.
“Working together, we can create global quality and regulatory systems that assure patient safety by enhancing product quality and authenticity throughout the supply chain,” vice chairwoman Lynne Byers wrote in an announcement of the meeting.
Teva receives FDA approval for colon cancer generic
JERUSALEM The Food and Drug Administration has approved a generic version of a colon cancer treatment.
Teva Pharmaceutical Industries announced last week the approval and launch of oxaliplatin, an injectable drug, in the 50 mg per 10 milliliter and 100 mg per 20 milliliter strengths. The drug is a generic version of Debiopharm’s and Sanofi-Aventis’ Eloxatin and is approved as an adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and treatment of advanced colorectal cancer.
In June, the U.S. District Court for the District of New Jersey ruled in Teva’s favor, finding that Teva did not infringe U.S. Patent No. 5,338,874, Debiopharm’s patent on Eloxatin. Sanofi and Debiopharm have appealed the decision, and Sanofi has sued the FDA seeking to rescind all approvals of generic oxaliplatin pending resolution of the appeal.
Eloxatin had sales of $1.3 billion in the United States last year, according to IMS Health data.
NACDS president, CEO Anderson joins Rep. Loebsack for pharmacy tours
IOWA CITY, Iowa The head of the largest organization representing the country’s retail pharmacy chains recently went on a short tour in the heartland.
The National Association of Chain Drug Stores announced Monday that president and CEO Steven Anderson accompanied Rep. Dave Loebsack, D-Iowa, in visiting an Iowa City, Iowa, Hartig Drug and a Mount Vernon, Iowa, Shepley Pharmacy in an effort to demonstrate pharmacy’s role in the healthcare system. Anderson is an alumnus of Mount Vernon’s Cornell College and serves on its board of trustees.
“It is my sincere honor to return to Iowa for this important healthcare event,” Anderson said in a statement. “These pharmacy tours will help to raise awareness of the vital role of pharmacy in fostering access to care, reducing healthcare costs and improving patient health and healthcare quality, and we appreciate Rep. Loebsack’s leadership and energetic participating.”
The tours followed the NACDS’ recent Pharmacy and Technology Conference in Boston and RxIMPACT, an advocacy program on Capitol Hill.